More　than　one　billion　people　worldwide　suffer　from　hypertension,　and　essential　arterial　hypertension　is　in　particular　a　major　risk　factor　for　cardiovascular　diseases.　These　conditions　can　lead　to　complications　such　as　stroke,　renal　failure,　cardiac　hypertrophy,　and　heart　failure.　Despite　extensive　research　on　various　antihypertensive　drugs,　an　increasing　number　of　people　are　unable　to　effectively　control　their　hypertension.　Further　optimization　of　their　treatment　is　required.　Given　the　pathogenesis　of　hypertension,　natural　products　(NPs)　have　emerged　as　a　promising　source　of　potential　antihypertensive　agents.　NPs　can　prevent　the　development　of　hypertension　by　targeting　oxidative　stress,　inflammation,　vascular　remodeling,　and　neurohormonal　pathways.　These　targets　provide　the　foundation　for　the　application　of　NPs　in　clinical　treatment.　This　review　assesses　NPs　with　potential　antihypertensive　activities　published　between　2019　and　2024.　A　total　of　70　unique　NPs　were　identified　through　PubMed　and　Web　of　Science.　Seventy　unique　NPs　were　categorized　into　flavonoids　(20　compounds),　terpenoids　(24　compounds),　alkaloids　(17　compounds),　and　plant-derived　extracts　(9　species).　These　products　were　classified　according　to　their　structural　frameworks,　and　their　bioactivities　were　briefly　summarized.　Future　research　should　prioritize　NPs　with　dual　anti-oxidant/anti-inflammatory　properties　for　clinical　experiments,　advanced　delivery　systems　for　improved　bioavailability,　and　interdisciplinary　approaches　integrating　synthetic　biology　for　scalable　production.